S9624 Ifosfamide in Treating Patients With Meningeal Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003292|
Recruitment Status : Terminated (lack of accrual)
First Posted : January 27, 2003
Last Update Posted : November 8, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
|Condition or disease||Intervention/treatment||Phase|
|Chondrosarcoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Rhabdomyosarcoma Adult Malignant Meningioma Adult Brain Malignant Hemangiopericytoma||Drug: ifosfamide||Phase 2|
- Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide.
- Evaluate toxicities of ifosfamide in this patient population.
OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors|
|Study Start Date :||July 1998|
|Actual Primary Completion Date :||January 2004|
|Actual Study Completion Date :||January 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003292
Show 70 Study Locations
|Study Chair:||Leslie McAllister, MD||Neurological Clinic|
|Study Chair:||Lynn G. Feun, MD||University of Miami Sylvester Comprehensive Cancer Center|